Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Hørsholm, Denmark, November 15, 2022 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include PEGS Europe Protein & Antibody Engineering Summit (November 14-16), the presentation of Q3 2022 results (November 17), and the BioStock Life Science Summit 2022 (November 29-30).
By attending relevant industry and investor events, the company aims to increase the awareness of the ExpreS[2] technology platform and its exciting development pipeline, including the novel ES2B-C001 HER2-cVLP breast cancer vaccine. More information on each event and how to register is found below and on the Company's website (https://expres2ionbio.com/meet-us-2/).
PEGS Europe - Protein & Antibody Engineering Summit, November 14-16, Barcelona, Spain
Meet ExpreS[2]ion's VP of R&D and Technology, Dr. Max M. Søgaard at the largest protein & antibody engineering event in Europe. More information and registration can be found on the PEGS Europe website (https://www.pegsummiteurope.com/).
Presentation of Q3 2022 results hosted by HC Andersen Capital, November 17 at 10:00 CET, Virtual
ExpreS[2]ion CEO Bent U. Frandsen and CFO Keith Alexander will discuss the Q3 2022 results and answer investors' questions. More information and registration can be found on the H.C. Andersen Capital Events website (https://hcandersencapital.dk/event/expres2ion-biotechnologies-presentation-of-q3-interim-report-2022/).
BioStock Life Science Summit 2022, November 30 at 14:40 CET, Medicon Village, Lund, Sweden
CEO Bent U. Frandsen will present ExpreS[2]ion to investors and potential investors. Registration is possible via the BioStock website (https://www.biostock.se/en/2022/01/biostock-life-science-summit-2022/).
Certified Adviser
Svensk Kapitalmarknadsgranskning AB